Form 4: Curis Inc. Director Martyn D Greenacre Reports Stock Option Grant

Director Martyn D Greenacre reports the acquisition of stock options in Curis Inc.

Summary

• Martyn D Greenacre, a director of Curis Inc. [CRIS], filed a Form 4 on January 30, 2025, reporting a transaction.
• The transaction involved the acquisition of 1,600 non-qualified stock options with an exercise price of $3.13 on January 28, 2025.
• These options vest 100% on January 28, 2026, and expire on January 27, 2035.
• Following the reported transaction, Greenacre directly owns 1,600 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly standard.
• Comparable companies in the biotech industry, such as Amgen, Gilead Sciences, and Biogen, also utilize stock options as part of their executive compensation packages.

Key Dates